<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228108</url>
  </required_header>
  <id_info>
    <org_study_id>pro-SWAP104622</org_study_id>
    <nct_id>NCT03228108</nct_id>
  </id_info>
  <brief_title>Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.</brief_title>
  <acronym>pro-SWAP</acronym>
  <official_title>The Effect of Rectal Swab Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy on Infectious Complications and Cost of Care: A Randomized Controlled Trial in the Netherlands.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effectiveness and cost-effectiveness of rectal swab&#xD;
      culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal&#xD;
      prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral&#xD;
      ciprofloxacin (control group), while the other half will receive rectal culture-guided oral&#xD;
      antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal&#xD;
      swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis,&#xD;
      comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative&#xD;
      oral antibiotic based on the culture results will be prescribed&#xD;
      (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin).&#xD;
&#xD;
      The investigators hypothesise that the targeted prophylaxis group (intervention group) will&#xD;
      have a lower rate of post-biopsy infectious complications compared to the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several classes of antibiotics are proven effective for prophylaxis during transrectal&#xD;
      prostate biopsy, reducing infectious complications to less than 1% in case of susceptible&#xD;
      rectal flora. Ciprofloxacin has been best studied and is recommended as first choice&#xD;
      prophylaxis in urology guidelines. However, due to increasing fluoroquinolone resistance in&#xD;
      gram negative bacilli (currently more than 20% in E.coli), a significant increase up to 6% in&#xD;
      infectious complications after transrectal prostate biopsy was recently noticed. Antibiotic&#xD;
      treatment of these infections and hospitalization may account for increased health care&#xD;
      associated costs and will contribute to the further development of antibiotic resistance.&#xD;
&#xD;
      Besides, in urology guidelines no clear recommendations are made on the duration of&#xD;
      prophylaxis. In the Netherlands, therefore, various prophylactic ciprofloxacin schedules are&#xD;
      used, of which 2 to 3 day regimens are most common. Prolonged duration of prophylaxis during&#xD;
      prostate biopsy is not proven to be more effective than a 1-day regimen, but it is more&#xD;
      likely to select more fluoroquinolone (FQ) resistance.&#xD;
&#xD;
      This study aims to assess the effectiveness and cost-effectiveness of rectal culture-guided&#xD;
      antimicrobial prophylaxis to reduce infectious complications after transrectal prostate&#xD;
      biopsy. Also, duration of antibiotic prophylaxis will be minimized to 24 hours, thereby&#xD;
      controlling further development of resistant bacteria.&#xD;
&#xD;
      The culture method used in this study with four phenotypic screening agars to support the&#xD;
      choice of one of the oral prophylactic antibiotics is innovative. Culture results become&#xD;
      available rapidly, within 48 hours, the method is simple, relatively inexpensive, as it does&#xD;
      not need full susceptibility testing of separate colonies, and useful in daily practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any registered clinical infectious complication after prostate biopsy</measure>
    <time_frame>within 7 days post-biopsy</time_frame>
    <description>Urinary tract infection, pyelonephritis, sepsis, fever, acute prostatitis, acute epididymitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost of care</measure>
    <time_frame>within 30 days after prostate biopsy</time_frame>
    <description>Difference of costs between the intervention and the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive microbiological results</measure>
    <time_frame>within 7 and 30 days after prostate biopsy</time_frame>
    <description>Urine or blood culture results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any registered clinical infectious complication after prostate biopsy</measure>
    <time_frame>within 7 and 30 days after prostate biopsy</time_frame>
    <description>Urinary tract infection, pyelonephritis, sepsis, fever, acute prostatitis, acute epididymitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization after prostate biopsy</measure>
    <time_frame>within 30 days after prostate biopsy</time_frame>
    <description>Any hospital admission, including ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>within 30 days after prostate biopsy</time_frame>
    <description>Mortality of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of used antibiotics</measure>
    <time_frame>within 30 days after prostate biopsy</time_frame>
    <description>All side effects mentioned in the Summary of Product Characteristics (SPC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of ciprofloxacin-resistant gram negative bacilli in local rectal flora</measure>
    <time_frame>rectal swabs are taken 14 days before biopsy</time_frame>
    <description>Assessed through microbiological rectal swab cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall antibiotic use after prostate biopsy</measure>
    <time_frame>within 30 days after prostate biopsy</time_frame>
    <description>Number of antibiotic prescriptions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1288</enrollment>
  <condition>Complication</condition>
  <condition>Infection</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Targeted antimicrobial prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:&#xD;
trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or&#xD;
fosfomycin 3 g orally 2 hours before prostate biopsy, or&#xD;
pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine empirical prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>see study arms.</description>
    <arm_group_label>Routine empirical prophylaxis</arm_group_label>
    <arm_group_label>Targeted antimicrobial prophylaxis</arm_group_label>
    <other_name>Ciproxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/Sulfamethoxazole</intervention_name>
    <description>see study arms.</description>
    <arm_group_label>Targeted antimicrobial prophylaxis</arm_group_label>
    <other_name>Co-trimoxazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin</intervention_name>
    <description>see study arms.</description>
    <arm_group_label>Targeted antimicrobial prophylaxis</arm_group_label>
    <other_name>Monuril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pivmecillinam/augmentin</intervention_name>
    <description>see study arms.</description>
    <arm_group_label>Targeted antimicrobial prophylaxis</arm_group_label>
    <other_name>Selexid</other_name>
    <other_name>Amoxicillin/clavulanic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form.&#xD;
&#xD;
          -  Subject undergoes a transrectal prostate biopsy as part of the standard care in the&#xD;
             Radboudumc (Nijmegen), Canisius Wilhelmina hospital (Nijmegen) or Catharina hospital&#xD;
             (Nijmegen) (because of suspicion of prostate cancer).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to receive ciprofloxacin (e.g. documented history of sensitivity to&#xD;
             medicinal products or excipients similar to those found in the antibiotic prophylaxis,&#xD;
             relevant history or presence of cardiovascular disorders)&#xD;
&#xD;
          -  Inability to receive either co-trimoxazole, fosfomycin and pivmecillinam/augmentin&#xD;
             prophylaxis for any reason (e.g. documented history of sensitivity to medicinal&#xD;
             products or excipients similar to those found in the antibiotic prophylaxis)&#xD;
&#xD;
          -  Inability to understand the nature of the trial and the procedures required.&#xD;
&#xD;
          -  Individuals with an urinary tract infection or acute prostatitis within 14 days prior&#xD;
             to intervention.&#xD;
&#xD;
          -  Individuals who receive antibiotics within 14 days before prostate biopsy.&#xD;
&#xD;
          -  Individuals who fail to send a rectum swab to the microbiology laboratory.&#xD;
&#xD;
          -  Individuals whose rectal swab shows no growth on a (growth) control MacConkey agar&#xD;
             without antibiotics.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heiman Wertheim, Prof. dr.</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bravis</name>
      <address>
        <city>Bergen Op Zoom</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Hospital</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bravis</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Hospital</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Tweesteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhoven Hospital</name>
      <address>
        <city>Uden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Culture-guided</keyword>
  <keyword>Targeted prophylaxis</keyword>
  <keyword>Prostate biopsy</keyword>
  <keyword>Antibiotic prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Amdinocillin Pivoxil</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

